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OBJECTIVE— 11--hydroxysteroid dehydrogenase type 1 (11HSD1) converts inactive
cortisone into active cortisol, thereby amplifying intracellular glucocorticoid action. The efficacy
and safety of the 11HSD1 inhibitor INCB13739 were assessed when added to ongoing met-
formin monotherapy in patients with type 2 diabetes exhibiting inadequate glycemic control
(A1C 7–11%).
RESEARCH DESIGN AND METHODS— This double-blind placebo-controlled par-
alleled study randomized 302 patients with type 2 diabetes (mean A1C 8.3%) on metformin
monotherapy (mean 1.5 g/day) to receive one of five INCB13739 doses or placebo once daily for
12 weeks. The primary end point was the change in A1C at study end. Other end points included
changes in fasting glucose, lipids, weight, adverse events, and safety.
RESULTS— After 12 weeks, 200 mg of INCB13739 resulted in significant reductions in A1C
(0.6%), fasting plasma glucose (24 mg/dl), and homeostasis model assessment–insulin re-
sistance (HOMA-IR) (24%) compared with placebo. Total cholesterol, LDL cholesterol, and
triglycerides were all significantly decreased in hyperlipidemic patients. Body weight decreased
relative to placebo after INCB13739 therapy. A reversible dose-dependent elevation in adreno-
corticotrophic hormone, generally within the normal reference range, was observed. Basal cor-
tisol homeostasis, testosterone in men, and free androgen index in women were unchanged by
INCB13739. Adverse events were similar across all treatment groups.
CONCLUSIONS— INCB13739 added to ongoing metformin therapy was efficacious and
well tolerated in patients with type 2 diabetes who had inadequate glycemic control with
metformin alone. 11HSD1 inhibition offers a new potential approach to control glucose and
cardiovascular risk factors in type 2 diabetes.
Diabetes Care 33:1516–1522, 2010
The phenotypic similarities betweenobesity, type 2 diabetes, and Cush-ing’s syndrome have sparked con-
siderable interest in the plausible role for
endogenous glucocorticoids in the patho-
genesis of type 2 diabetes. 11HSD1 is an
11-reductase that catalyzes the intracel-
lular conversion of inactive cortisone into
active cortisol (1). 11HSD1 is expressed
in specific tissues, most notably in liver,
adipose, vasculature, brain, and macro-
phages (2,3), where it increases intracel-
lular cortisol levels but does not participate
in adrenal cortisol biosynthesis from choles-
terol. 11HSD1 activity is elevated in adi-
pose tissue of obese rodents and humans
(4,5). Mice engineered with similarly in-
creased adipose tissue 11HSD1 activity
exhibit increased weight and visceral fat
mass, insulin resistance, hyperlipidemia,
hyperphagia, and hypertension (6,7). Re-
duction of intracellular glucocorticoid lev-
els via 11HSD1 gene deletion (8–10),
inhibition (11), or ectopic expression of the
cortisol-inactivating enzyme 11HSD2 in
adipose tissue (12) is sufficient to drive re-
sistance to weight gain on a high-fat diet,
improve glucose tolerance and insulin sen-
sitivity, and attenuate dyslipidemia in ro-
dents. These data suggest that 11HSD1
inhibition may provide a novel treatment to
reduce hyperglycemia and macrovascular
disease risk in type 2 diabetes.
INCB13739 is an oral and selective
11HSD1 inhibitor being developed to
treat type 2 diabetes. We conducted a 12-
week dose-ranging study of INCB13739
added to ongoing metformin mono-
therapy in patients with type 2 diabetes to
evaluate the safety and efficacy of this
compound.
RESEARCH DESIGN AND
METHODS— This was a double-
blind randomized paralleled trial con-
ducted at 74 sites in the U.S. and six sites
in Puerto Rico (NCT00698230). The
study consisted of five periods: screening,
metformin dose stabilization, 14-day pla-
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cebo single-blind run-in, 12-week dou-
ble-blind treatment, and 3-week off-
treatment follow-up. The study was
conducted pursuant to the Declaration of
Helsinki and was approved by institu-
tional review boards at participating sites.
Patients provided informed consent be-
fore screening.
Patients (18–75 years) with type 2 di-
abetes, a BMI between 25 and 45 kg/m2,
and A1C between 7–11% while taking
metformin monotherapy at a stable dose
for 10 weeks were eligible. Exclusion
criteria included a medical history of dis-
orders involving glucocorticoid, miner-
alocorticoid, or androgen excess; a history
of type 1 diabetes or secondary forms of
diabetes; previous insulin therapy; tri-
glycerides 500 mg/dl; and treatment
with any oral, systemic, topical, or in-
haled glucocorticoids, thiazolidinedi-
ones, or exenatide within 3 months of
screening. No inclusion criteria were
specified for cholesterol or blood pressure
and patients could enter the study on
(and maintain) any hypolipidemic or an-
tihypertensive regimen.
Patients were randomized equally to
once-daily INCB13739 (5, 15, 50, 100, or
200 mg) or placebo. Dose selection was
based on phase 1 pharmacokinetic and
pharmacodynamic data, with the goal of
evaluating regimens that achieve different
degrees of inhibition, from 50 to
90%, with the duration of inhibition
varying across the five dose levels. Pa-
tients with a fasting plasma glucose (FPG)
270 mg/dl through week 8 or 240
mg/dl subsequently were discontinued
and offered rescue therapy.
The primary end points were the
change from baseline to week 12 com-
pared with placebo in A1C, safety, and
tolerability. Secondary end points in-
cluded the change from baseline to week
12 compared with placebo in FPG and
lipid profiles and the proportion of pa-
tients achieving an A1C7% at week 12.
Tertiary end points included the change
from baseline in homeostasis model as-
sessment–insulin resistance (HOMA-IR),
weight, blood pressure, and the propor-
tion of patients meeting rescue therapy
criteria.
Study assessments
On-treatment study visits occurred at
weeks 2, 4, 8, and 12 and a follow-up visit
at week 15 off treatment. Fasting blood
samples were collected after a minimum
10-h fast. Salivary samples were collected
between 2200 and 2400. All assays were
performed by Covance Central Labs.
Monitoring for adverse events (AEs) (in-
tensity, duration, outcome, and causal-
ity), physical examinations, vital signs,
body weight and morphometrics, 12-lead
electrocardiograms, and safety laboratory
assessments including hematology, se-
rum chemistry, and urinalysis were also
performed.
Statistical analysis
There were 40 patients per group com-
pleting week 12 who provided 90%
power to detect a mean 0.6% difference in
A1C between the 200-mg group and pla-
cebo assuming an Emax dose-response
model (13) with a half-maximal stimula-
tion (ED50) of 30 mg and an SD in A1C of
1.2%. This Emax model is commonly used
for phase 2 dose-ranging studies and was
prespecified with the following optimal
linear contrast: 0.45666 (placebo),
0.31381 (5 mg), 0.12333 (15 mg),
0.168336 (50 mg), 0.312566 (100 mg),
and 0.412901 (200 mg) based on the
half-maximal concentration (ED50)  30
mg assumption. The study was powered
for A1C alone and not for lipids or blood
pressure. Two populations were prespeci-
fied: the evaluable analysis set was de-
fined as all patients randomized who have
completed the 12 weeks of study treat-
ment with 80% compliance; and the
full analysis set was defined as all patients
randomized who have taken at least one
dose of study drug with any missing
week 12 data imputed by last observa-
tion carried forward. The A1C and FPG
end points were prespecified to be ana-
lyzed using the evaluable analysis set;
all other efficacy end points were pre-
specified to be analyzed using the full
analysis set.
For all end points, treatment effect
was assessed using a linear model with
treatment as the model factor and baseline
as a covariate. Changes from baseline
were estimated with 90% CIs from the
model.
RESULTS— The disposition of pa-
tients is in supplementary Fig. 1, found in
an online appendix available at http://
care.diabetesjournals.org/cgi/content/full/
dc09-2315/DC1. Baseline assessments
were performed in 302 patients who en-
tered the treatment phase of the study,
and 228 patients (75%) completed the
12-week treatment period. The most
common reasons for discontinuation
were loss to follow-up (5%), withdrawal
of consent (5%), lack of efficacy (4%),
noncompliance with study procedures/
medication (4%), and adverse events
(4%), none of which related to the dose
level of study medication. The clinical
characteristics of the population at base-
line were similar between treatment
groups (supplementary Table 1): the
mean duration of diabetes was 6.2 years,
BMI 32.4 kg/m2, A1C 8.3%, and FPG 173
mg/dl.
Efficacy
At week 12, treatment with INCB13739
resulted in a dose-dependent reduction in
A1C (PEmax  0.016; Table 1, Fig. 1A).
The placebo-adjusted least-squares (LS)
mean difference from baseline in A1C
reached statistical significance for the
100-mg (0.47%; P 0.05) and 200-mg
(0.56%; P  0.01) groups. A1C de-
creased compared with placebo in a time-
dependent manner, reaching its maximum
at week 12 (Fig. 1B). A greater proportion of
patients (25%) randomized to 100 or 200
mg INCB13739 achieved an A1C 7%
when compared with placebo (9.5%) at
week 12. In a predefined subgroup analysis
in patients with a baseline A1C 8%, the
response to INCB13739 was more pro-
nounced, with the 50-, 100-, and 200-mg
groups achieving a significant (P  0.05)
change in A1C from baseline of 0.65 to
0.72%. The placebo-adjusted change in
A1C for the 100- and 200-mg groups was
greater in subjects with a baseline BMI30
kg/m2 (0.53% and0.93%, respectively)
than in subjects with a baseline BMI 30
kg/m2 (0.35% and 0.17%, respec-
tively). The number of patients requiring
rescue therapy (12) did not differ signifi-
cantly between treatment groups. FPG de-
creased in a dose- and time-dependent
manner in the 100- and 200-mg treatment
groups (Fig. 1C) and reached statistical sig-
nificance (P  0.01) from placebo in the
200-mg group with an LS mean difference
of 24.1 mg/dl. A dose-dependent reduc-
tion in HOMA-IR was observed, reaching
significance (P  0.05) in the 200-mg
group with an LS mean difference of1.32
(24%), suggesting an insulin-sensitizing
mechanism of action.
Body weight decreased with INCB13739
treatment, with statistical significance
from baseline (P  0.05) achieved in the
15 (0.6 kg), 100 (1.1 kg), and 200 mg
(0.9 kg) treatment groups (Table 1).
Waist-to-hip ratio did not change with
treatment.
Plasma lipids and blood pressure
were generally well controlled at baseline
(supplementary Table 1). Treatment with
Rosenstock and Associates
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INCB13739 resulted in a modest dose-
dependent (Ptrend  0.026) decrease in
total cholesterol, reaching a maximum of
7 mg/dl (3%) from baseline in the
200-mg group (Table 1). In a prespecified
analysis, patients with Adult Treatment
Panel (ATP) III defined hyper-lipidemia
(total cholesterol 200 mg/dl; LDL cho-
lesterol130 mg/dl) or hyper-triglyceride-
mia (200 mg/dl) at baseline exhibited a
greater improvement, reaching statistical
significance (P  0.05) in the 100-mg
group for all three lipid categories (cho-
lesterol 16 mg/dl, 6%; LDL 17 mg/
dl, 10%; triglycerides 74 mg/dl,
16%). Similar responses were observed
in the 200-mg group, but these did not
reach significance, possibly because of the
smaller size of the subgroups. Changes in
HDL and free fatty acids were not signifi-
cantly different between the treatment
groups. Systolic and diastolic blood pres-
sure did not change appreciably during
the study.
Safety
Treatment with INCB13739 was well tol-
erated and AEs were reported at similar
frequencies across all treatment groups
(Table 2). No drug-related serious AEs oc-
curred in the trial. One death occurred in
the 200-mg group because of complica-
tions after a serious AE of acute ischemia
of the lower extremities. This AE occurred
2 weeks after the last dose of study med-
ication in a subject with preexisting con-
gestive heart failure and aortic valvular
disease. The death was due to cardiac
arrest immediately after induction of
anesthesia before bilateral iliofemoral
embolectomy. The AE was judged by the
investigator as unrelated to study med-
ication. No hypoglycemic events were
reported during the treatment phase of
the trial. The most frequent AEs re-
ported were typical for this population
and did not exhibit dose dependence.
There were four reports of nausea in the
200-mg group (compared with one in
the placebo group); however, all of
these resolved during continued dosing
and three were categorized by the inves-
tigator as unrelated to study medica-
tion. There were no clinically relevant
differences between treatment groups
in electrocardiograms, hematology, se-
rum chemistry, or urinalysis.
The anticipated compensatory activa-
tion of the hypothalamic-pituitary-
adrenal axis to overcome reduced cortisol
regeneration on 11HSD1 inhibition was
evaluated. INCB13739 caused a dose-
related increase in morning plasma ACTH
and the ACTH-sensitive adrenocortico-
steroid dehydroepiandrosterone sulfate
(DHEAS) levels, although mean concen-
trations of both hormones remained
within laboratory reference ranges (Table
2). ACTH and DHEAS rises after
INCB13739 reached a plateau at week 4
(102 and 54%, respectively, versus
19 and 6% in the placebo group); did
not exhibit a further increase at week 12,
even in the 200-mg treatment group
(114% and55%, respectively); and re-
turned to baseline levels by the 3-week fol-
low-up visit (Fig. 2A and B). Morning
plasma cortisol and evening salivary cortisol
levels were unaltered by INCB13739 at any
dose (Fig. 2C), suggesting that the rise in
ACTH was a compensatory response.
DHEAS is a precursor for androgen
biosynthesis. INCB13739 treatment re-
sulted in a dose-related increase in morn-
Figure 1—Glycemic efficacy. A: LS mean (SE) change from baseline in A1C at week 12. B: LS
mean difference (SE) from placebo in A1C from baseline toweek 12 in the 100-mg (F) and 200-mg
(E) treatment groups. C: LS mean difference (SE) from placebo in FPG from baseline to week 12
in the 100- and 200-mg treatment groups. *P  0.1, †P  0.05, ‡P  0.01, active vs. placebo
(PBO).
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ing fasting serum androstenedione (A4),
although mean concentrations remained
within the laboratory reference range (Ta-
ble 2). In males, there were no differences
between treatment groups in total testos-
terone, sex hormone–binding globulin
(SHBG), or free androgen index (FAI). In
females, total testosterone (available at
baseline and week 8) increased in a dose-
dependent manner with mean concentra-
tions within the laboratory reference
range. Maximal concentrations were ob-
served in the 200-mg group (1.8 vs. 1.3
nmol/l in the placebo group; P  0.05).
These changes occurred alongside mod-
est increases in SHBG (assessed at week
12), apparent in the 50- and 100-mg
groups (P  0.05), but not the 200-mg
group. Importantly, there were no signif-
icant differences between treatment
groups in calculated FAI in females (pla-
cebo  6.9; INCB13739 range 
5.7–8.2).
CONCLUSIONS— The results from
this study indicate, for the first time, that
decreasing local cortisol exposure
through 11HSD1 inhibition improves
hyperglycemia over 12 weeks in patients
with type 2 diabetes. The addition of
once-daily INCB13739 in patients inade-
quately controlled with metformin signif-
icantly reduced A1C, FPG, and HOMA-
IR. These effects were dose dependent,
and the greatest improvements were
achieved at the highest dose administered
(200 mg), with evidence for a more pro-
found A1C reduction in subjects with a
BMI 30 kg/m2, compatible with ele-
vated 11HSD1 in adipose tissue in
obesity. Preliminary data from pharmaco-
kinetic analyses (data not shown) indicate
that the 100- and 200-mg groups
achieved, 4 h after administration, mean
free drug exposures that reached 100 mg
or exceeded 200 mg, the concentrations
required to inhibit 90% of the enzyme ac-
tivity in cellular assays; however, only the
200-mg group retained such a mean ex-
posure at the end of the dosing interval.
Thus, glycemic efficacy may be associated
with a high degree of enzyme inhibition,
and it is possible that greater glycemic im-
provement might be achieved with in-
creased dose levels or frequency of
administration.
Plasma lipids were generally well con-
trolled in this population, and 30% of pa-
tients were receiving lipid-lowering
medications. INCB13739 treatment re-
sulted in a dose-dependent reduction in
total cholesterol, and while of modest
magnitude, these changes also associated
with directional beneficial trends in LDL
cholesterol and triglycerides. Of interest,
patients who met ATP III criteria for “bor-
derline high” LDL cholesterol (130 mg/
dl), total cholesterol (200 mg/dl), or
“hyper-triglyceridemia” (200 mg/dl)
exhibited a larger improvement in all
three lipid parameters. The magnitude of
effect was equivalent in the 100- and
200-mg groups, reaching statistical sig-
nificance for the 100-mg group, which
had the largest subgroup size.
INCB13739 treatment resulted in a
dose-dependent modest decrease in body
weight of1 kg at the highest dose stud-
Table 1—Efficacy assessments
Placebo 5 mg 15 mg 50 mg 100 mg 200 mg
Baseline A1C (%) 8.3  1 8.2  1 8.3  1 8.3  1 8.2  1 8.2  1
A1C (%) 0.09  0.1 0.21  0.1* 0.11  0.1 0.09  0.2 0.38  0.1† 0.47  0.1‡#
A1C 8% 0.10  0.2 0.39  0.2 0.24  0.2 0.65  0.3* 0.72  0.2† 0.65  0.2*#
Subgroup n 23 23 18 11 16 19
BMI 30 kg/m2 0.17  0.1 0.24  0.2*§ 0.10  0.2 0.25  0.2* 0.36  0.2† 0.76  0.2‡#
Subgroup n 29 23 26 15 26 18
Baseline FPG (mg/dl) 179  51 172  41 175  44 178  53 170  64 165  41
FPG (mg/dl) 12.6  6.1 6.0  6.3 2.3  6.4 4.7  7.2* 1.6  6.1* 11.5  6.2‡§
C-peptide (pmol/l) 9.48  40 9.84  41 14.0  41 39.6  45 32.2  39 47.4  40
HOMA-IR 0.25  0.4 0.29  0.4 0.33  0.4 0.42  0.5 0.51  0.4 1.06  0.4†
HOMA-B 3.9  4.1 3.92  4.2 4.78  4.2 6.67  4.6* 2.35  4.1 2.58  4.1
Cholesterol (mg/dl) 1.2  4 0.7  4 1.2  4 3.9  4 6.6  4* 7.3  4*
200 mg/dl 10.0  6 11.6  5 12.4  7 1.5  7 16.2  5 18.5  6§
Subgroup n 19 22 14 12 28 20
LDL cholesterol (mg/dl) 2.3  4 1.2  4 0.4  4 7.0  4§ 4.6  3§ 4.3  3
130 mg/dl 8.5  8 19.3  8 9.7  9 8.5  13 17.0  6 14.3  8
Subgroup n 12 10 9 6 18 12
HDL cholesterol (mg/dl) 0.8  1.3 0.4  1.2 1.2  1.3 1.2  1.4 0.4  1.2 0.8  1.2
40 mg/dl 3.5  1.9§ 0.8  2.0 2.7  1.6 2.7  1.7 5.0  2.0 1.9  1.8
Subgroup n 13 12 21 17 14 14
Triglyceride (mg/dl) 0.0  12 4.4  12 27.4  5 12.4  13 11.5  12 10.6  12
200 mg/dl 19.5  28 3.5  28 105.3  31 57.5  29 74.3  27 55.8  29
Subgroup n 16 17 13 15 18 15
FFA (mmol/l) 0.0  0.03 0.03  0.03 0.02  0.03 0.01  0.03 0.03  0.03 0.0  0.03
Systolic blood pressure (mmHg) 0.9  1.6 0.3  1.5 0.17  1.6 1.2  1.6 0.5  1.5 0.4  1.5
Diastolic blood pressure (mmHg) 1.2  1.0 0.0  1.0 1.4  1.0 0.2  1.1 0.5  1.0 0.8  1.0
Weight (kg) 0.2  0.3 0.5  0.3§ 0.6  0.4 0.0  0.4 1.1  0.3* 0.9  0.3#
Waist-to-hip ratio 0.01  0.01 0.02  0.01* 0.0  0.01 0.01  0.01 0.02  0.01 0.01  0.01
Data are LS mean change from baseline  SEM unless noted. *P  0.1, †P  0.05, ‡P  0.01, active vs. PBO. §P  0.1, P  0.05, #P  0.01, week 12 vs.
baseline.
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ied. This change was time dependent and
did not plateau over the 12-week treat-
ment period (data not shown). The thia-
zolidinedione insulin sensitizers increase
body weight through adipocyte differen-
tiation (14,15). As cortisol can drive adi-
pocyte differentiation and expansion
(16), it is possible that attenuating cortisol
signaling in adipose may decrease adipo-
cyte size. This has been reported in pre-
clinical models with an 11HSD1
inhibitor (17) and suggests the potential
for positive effects of INCB13739 on total
body weight and/or regional adiposity
with longer exposure.
INCB13739 was well tolerated at all
dose levels, and there were no differences
in AE frequency relative to placebo nor
were there any apparent dose-dependent
changes in AEs.
While 11HSD1 is not involved in
adrenal cortisol biosynthesis, 11HSD1
activity within the splanchnic bed does
contribute25% of total cortisol produc-
tion (18). An expected consequence of
11HSD1 inhibition is increased clear-
ance of cortisol and compensatory hypo-
thalamic-pituitary-adrenal axis activation
to maintain blood cortisol concentra-
tions. INCB13739 treatment did result in
a dose-related increase in ACTH levels
that was generally within the normal ref-
erence range. The ACTH response
reached a plateau with the 50-mg dose at
week 4, suggesting that the maximal re-
sponse to INCB13739 had been realized.
This plateau in ACTH and its rapid return
to baseline levels after cessation of therapy
are consistent with an adaptive endocrine
process driven by reversible 11HSD1 in-
hibition. Importantly, cortisol levels and
circadian rhythm were unaltered by
INCB13739 treatment. These data indi-
cate normal hypothalamic-pituitary-
adrenal axis function after 12 weeks of
INCB13739 therapy that adjusted appro-
priately to the inhibition of 11HSD1 ac-
t iv i ty to mainta in basa l cor t i so l
homeostasis. The leftward shift in the
ACTH dose relationship relative to effi-
cacy might reflect a greater contribution
of hepatic 11HSD1 inhibition to
splanchnic cortisol reactivation.
Aldosterone and renin were unaltered
by INCB13739 treatment (Table 2), and
serum electrolytes were unchanged (sup-
plementary Table 2). Modest elevations in
the androgenic precursors DHEAS and
A4 paralleled changes in ACTH. Like
ACTH, these changes were generally
within the reference range, plateaued
with respect to both dose and time, and
were reversed at follow-up. The highest
concentration of DHEAS observed in this
study (13.2 	mol/l in males and females)
is equivalent to levels observed after 50
mg/day dehydroepiandrosterone supple-
ment use (19). In men, there was no
change in plasma testosterone, SHBG, or
FAI after INCB13739 treatment, consis-
tent with the testes being the main source
of androgens. In females, a modest rise in
Table 2—End point endocrine assessments and safety summary
Reference range Placebo 5 mg 15 mg 50 mg 100 mg 200 mg
Endocrinology
ACTH 1.6–13.9 pmol/l 4.9  0.9 8.3  0.9‡ 7.1  0.9 9.2  1.0‡ 9.4  0.9‡ 11.2  0.9‡
Aldosterone 111–859 pmol/l 218  23 198  24 208  25 204  28 204  23 276  24
Renin 3.5–65.6 pg/ml 24.9  7.6 26.0  7.5 38.1  7.8 19.8  8.7 18.7  7.3 28.0  7.5
DHEAS,  0.14–18.73 	mol/l 4.1  0.6 3.7  0.6 5.2  0.6 5.0  0.7 5.4  0.6 6.6  0.7‡
DHEAS,  0.19–10.61 	mol/l 2.3  0.6 3.5  0.7 4.2  0.6† 3.4  0.7 3.5  0.6 4.0  0.6†
A4,  0.8–2.9 ng/ml 1.7  0.2 1.5  0.1 2.1  0.2 1.7  0.2 2.1  0.2 2.6  0.2‡
A4,  1.0–4.3 ng/ml 1.1  0.2 1.6  0.3 1.9  0.3† 2.2  0.3‡ 1.6  0.2 1.8  0.2†
T,  6.1–27.1 nmol/l 12.7  0.9 11.5  0.8 10.4  0.9 12.0  1.0 11.3  0.9 13.9  0.9
Ta,  0.4–2.6 nmol/l 1.3  0.4 1.5  0.3 1.7  0.8† 1.6  0.5 1.6  0.6 1.8  0.8†
SHBG,  7–70 nmol/l 25.9  3.2 29.9  2.8 20.6  3.1 23.5  3.7 20.8  3.1 29.7  3.4
SHBG,  15–120 nmol/l 23.0  5.1 27.1  6.1 30.8  5.8 39.9  6.4† 40.0  5.1† 24.9  5.1
FAI,  NA 63.9  5.8 43.5  5.0 60.2  5.5 55.8  6.6 62.7  5.7 53.3  6.2
FAIa,  NA 6.9  1.1 7.9  1.3 8.2  1.2 5.7  1.4 7.2  1.1 7.9  1.1
Safety and tolerability
1 AE 23 (46) 25 (49) 22 (44) 27 (57) 25 (47) 20 (39)
Rx-related* 3 (6) 8 (16) 8 (16) 9 (19) 4 (8) 5 (10)
1 SAE 0 (0) 1 (2) 0 (0) 0 (0) 1 (2) 1 (2)
Rx-related* 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
d/c for AE 2 (4) 2 (4) 2 (4) 3 (6) 1 (2) 1 (2)
AEs occurring in 3%
Nasopharyngitis 1 (2) 4 (8) 3 (6) 5 (11) 3 (6) 1 (2)
Diarrhea 3 (6) 3 (6) 1 (2) 3 (6) 3 (6) 1 (2)
Upper respiratory
tract infection
3 (6) 3 (6) 2 (4) 2 (4) 2 (4) 1 (2)
Headache 3 (6) 2 (4) 5 (10) 1 (2) 1 (2) 0 (0)
Arthralgia 0 (0) 7 (14) 1 (2) 2 (4) 0 (0) 0 (0)
Cough 0 (0) 1 (2) 2 (4) 1 (2) 3 (6) 2 (4)
Nausea 1 (2) 2 (4) 0 (0) 1 (2) 1 (2) 4 (8)
Endocrine data are week 12 LS meanSEM unless otherwise noted. Androgens and their precursors are categorized by sex. Central lab normal reference ranges are
provided. Treatment emergent AE data are n (%) for all AEs or for those occurring in at least 3% of patients. A4, androstenedione; d/c, discontinuation; FAI, free
androgen index; SAE, serious adverse event; T, testosterone. *Determined by the investigator to be possibly, probably, or definitely drug related. †P 0.05; ‡P
0.01, active vs. PBO. aT and FAI reflects week 8 concentrations.
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total testosterone at week 8 was observed
that was paralleled by a rise in SHBG such
that the resulting FAI calculation was not
significantly different in any INCB13739
group compared with placebo or baseline
levels. SHBG is known to increase in re-
sponse to improved insulin sensitivity
(20), and whether the changes observed
in this study reflect this or result from
more complex endocrine adaptation to
small changes in total testosterone are un-
known. Importantly, FAI is an accepted
surrogate in clinical practice for free tes-
tosterone and a marker of biologic andro-
gen activity in women (21). No signs or
symptoms of androgen excess were ob-
served, and longer-term studies will be
required to ascertain the clinical relevance
of the small androgen changes observed.
In summary, in patients with type 2
diabetes who had inadequate glycemic
control with metformin alone, the addi-
tion of once-daily INCB13739 was well
tolerated and resulted in significant im-
provements in A1C, FPG, and HOMA-IR.
INCB13739 treatment decreased body
weight and improved cholesterol and
triglycerides in patients with hyper-
lipidemia at baseline. 11HSD1 inhibi-
tion offers a new potential approach to
control glucose and cardiovascular risk
factors in type 2 diabetes. Further clinical
characterization of INCB13739 with long-
term controlled studies is warranted.
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